ESMO Asia 2025
Gene Solutions Satellite
Symposium
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
K-CONNECT PLATFORM
Empowering the Potential of
ctDNA-MRD
ESMO Asia 2025
Gene Solutions Satellite
Symposium
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
K-CONNECT PLATFORM
Empowering the Potential of
ctDNA-MRD
ESMO Asia 2025
Gene Solutions Satellite
Symposium
The Unique Combination of Multi-dimensional Genomics & AI in Cancer Care
Detection
Early cancer detection by screening for tumor DNA in the blood (ctDNA).
Profiling
Next-generation sequencing (NGS) tumor profiling for precision therapies.
Monitoring
Personalized ctDNA monitoring for recurrence risk and treatment responses.
Innovation
Discovery of multi-omics targets for new drug insights and novel therapies development.
News & Updates
Get the latest news and updates of our company and medical field.
Highlight Takeaways from the APAC Precision Oncology Conference 2025
On November 1, Hong Kong hosted a regional meeting focused on the evolving role of precision oncology. The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test.
K-TRACK Performance Validated in JTO Clinical and Research Reports: A Direct Comparison of Tumor‑Informed and Tumor‑Naïve ctDNA‑MRD Testing in Early‑Stage NSCLC
Gene Solutions is pleased to announce the publication of our latest research in JTO Clinical and Research Reports, evaluating the K-TRACK portfolio entitled: “Direct Comparison of Tumor-Informed and Tumor-Naïve ctDNA
Two Best Poster Awards at ESMO Asia 2025
This year at ESMO Asia 2025 in Singapore, the R&D team from Gene Solutions was honored with two Best Poster Awards — recognition that reflects not only scientific excellence, but
Bridging Genomic Insights: AI‑Powered Liquid Biopsy and Multi‑Omics at ESMO Asia Congress 2025
At ESMO Asia Congress 2025 (December 5–7), Gene Solutions’ Industry Satellite Symposium brought together leading voices from across the region to examine how AI-driven liquid biopsy and multi‑omics are reshaping
Gene Solutions at POGS 2025: Advancing Precision & Preventive Care
PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310
Gene Solutions Announces Publication in Cancer Medicine Showcasing Integrated Tumor DNA-RNA Profiling with Longitudinal ctDNA Monitoring
Gene Solutions today announced the publication of a peer-reviewed study using the K-4CARE assay in Cancer Medicine entitled “Tumor Genomic and Transcriptomic Analysis Integrated with Liquid Biopsy ctDNA Monitoring: Analytical
Symposium Summary: Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders
As part of our ongoing education series for OBGYNs on the evolution of Non-Invasive Prenatal Testing (NIPT), we successfully hosted the symposium “Expanding Horizons in NIPT – From Aneuploidy to
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
New Study Validates Tumor-Naïve, Multi-omics ctDNA Assay Performance for MRD Detection and Recurrence Prediction Across Solid Tumors
Real-world evidence shows high specificity and practical utility when tissue is unavailable, supporting relapse prediction, treatment surveillance and real-time resistance monitoring. Gene Solutions today announced the publication of a new
Highlight Takeaways from the APAC Precision Oncology Conference 2025
On November 1, Hong Kong hosted a regional meeting focused on the evolving role of precision oncology. The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test.
K-TRACK Performance Validated in JTO Clinical and Research Reports: A Direct Comparison of Tumor‑Informed and Tumor‑Naïve ctDNA‑MRD Testing in Early‑Stage NSCLC
Gene Solutions is pleased to announce the publication of our latest research in JTO Clinical and Research Reports, evaluating the K-TRACK portfolio entitled: “Direct Comparison of Tumor-Informed and Tumor-Naïve ctDNA
Two Best Poster Awards at ESMO Asia 2025
This year at ESMO Asia 2025 in Singapore, the R&D team from Gene Solutions was honored with two Best Poster Awards — recognition that reflects not only scientific excellence, but
Bridging Genomic Insights: AI‑Powered Liquid Biopsy and Multi‑Omics at ESMO Asia Congress 2025
At ESMO Asia Congress 2025 (December 5–7), Gene Solutions’ Industry Satellite Symposium brought together leading voices from across the region to examine how AI-driven liquid biopsy and multi‑omics are reshaping
Gene Solutions at POGS 2025: Advancing Precision & Preventive Care
PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310
Gene Solutions Announces Publication in Cancer Medicine Showcasing Integrated Tumor DNA-RNA Profiling with Longitudinal ctDNA Monitoring
Gene Solutions today announced the publication of a peer-reviewed study using the K-4CARE assay in Cancer Medicine entitled “Tumor Genomic and Transcriptomic Analysis Integrated with Liquid Biopsy ctDNA Monitoring: Analytical
Symposium Summary: Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders
As part of our ongoing education series for OBGYNs on the evolution of Non-Invasive Prenatal Testing (NIPT), we successfully hosted the symposium “Expanding Horizons in NIPT – From Aneuploidy to
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
New Study Validates Tumor-Naïve, Multi-omics ctDNA Assay Performance for MRD Detection and Recurrence Prediction Across Solid Tumors
Real-world evidence shows high specificity and practical utility when tissue is unavailable, supporting relapse prediction, treatment surveillance and real-time resistance monitoring. Gene Solutions today announced the publication of a new
Highlight Takeaways from the APAC Precision Oncology Conference 2025
On November 1, Hong Kong hosted a regional meeting focused on the evolving role of precision oncology. The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test.
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
New Study Validates Tumor-Naïve, Multi-omics ctDNA Assay Performance for MRD Detection and Recurrence Prediction Across Solid Tumors
Real-world evidence shows high specificity and practical utility when tissue is unavailable, supporting relapse prediction, treatment surveillance and real-time resistance monitoring. Gene Solutions today announced the publication of a new
Highlight Takeaways from the APAC Precision Oncology Conference 2025
On November 1, Hong Kong hosted a regional meeting focused on the evolving role of precision oncology. The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test.
K-TRACK Performance Validated in JTO Clinical and Research Reports: A Direct Comparison of Tumor‑Informed and Tumor‑Naïve ctDNA‑MRD Testing in Early‑Stage NSCLC
Gene Solutions is pleased to announce the publication of our latest research in JTO Clinical and Research Reports, evaluating the K-TRACK portfolio entitled: “Direct Comparison of Tumor-Informed and Tumor-Naïve ctDNA
Two Best Poster Awards at ESMO Asia 2025
This year at ESMO Asia 2025 in Singapore, the R&D team from Gene Solutions was honored with two Best Poster Awards — recognition that reflects not only scientific excellence, but
Bridging Genomic Insights: AI‑Powered Liquid Biopsy and Multi‑Omics at ESMO Asia Congress 2025
At ESMO Asia Congress 2025 (December 5–7), Gene Solutions’ Industry Satellite Symposium brought together leading voices from across the region to examine how AI-driven liquid biopsy and multi‑omics are reshaping
Gene Solutions at POGS 2025: Advancing Precision & Preventive Care
PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310
Gene Solutions Announces Publication in Cancer Medicine Showcasing Integrated Tumor DNA-RNA Profiling with Longitudinal ctDNA Monitoring
Gene Solutions today announced the publication of a peer-reviewed study using the K-4CARE assay in Cancer Medicine entitled “Tumor Genomic and Transcriptomic Analysis Integrated with Liquid Biopsy ctDNA Monitoring: Analytical
Symposium Summary: Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders
As part of our ongoing education series for OBGYNs on the evolution of Non-Invasive Prenatal Testing (NIPT), we successfully hosted the symposium “Expanding Horizons in NIPT – From Aneuploidy to
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
New Study Validates Tumor-Naïve, Multi-omics ctDNA Assay Performance for MRD Detection and Recurrence Prediction Across Solid Tumors
Real-world evidence shows high specificity and practical utility when tissue is unavailable, supporting relapse prediction, treatment surveillance and real-time resistance monitoring. Gene Solutions today announced the publication of a new
Highlight Takeaways from the APAC Precision Oncology Conference 2025
On November 1, Hong Kong hosted a regional meeting focused on the evolving role of precision oncology. The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test.
K-TRACK Performance Validated in JTO Clinical and Research Reports: A Direct Comparison of Tumor‑Informed and Tumor‑Naïve ctDNA‑MRD Testing in Early‑Stage NSCLC
Gene Solutions is pleased to announce the publication of our latest research in JTO Clinical and Research Reports, evaluating the K-TRACK portfolio entitled: “Direct Comparison of Tumor-Informed and Tumor-Naïve ctDNA
Two Best Poster Awards at ESMO Asia 2025
This year at ESMO Asia 2025 in Singapore, the R&D team from Gene Solutions was honored with two Best Poster Awards — recognition that reflects not only scientific excellence, but
Bridging Genomic Insights: AI‑Powered Liquid Biopsy and Multi‑Omics at ESMO Asia Congress 2025
At ESMO Asia Congress 2025 (December 5–7), Gene Solutions’ Industry Satellite Symposium brought together leading voices from across the region to examine how AI-driven liquid biopsy and multi‑omics are reshaping
Gene Solutions at POGS 2025: Advancing Precision & Preventive Care
PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310
Gene Solutions Announces Publication in Cancer Medicine Showcasing Integrated Tumor DNA-RNA Profiling with Longitudinal ctDNA Monitoring
Gene Solutions today announced the publication of a peer-reviewed study using the K-4CARE assay in Cancer Medicine entitled “Tumor Genomic and Transcriptomic Analysis Integrated with Liquid Biopsy ctDNA Monitoring: Analytical
Symposium Summary: Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders
As part of our ongoing education series for OBGYNs on the evolution of Non-Invasive Prenatal Testing (NIPT), we successfully hosted the symposium “Expanding Horizons in NIPT – From Aneuploidy to
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
New Study Validates Tumor-Naïve, Multi-omics ctDNA Assay Performance for MRD Detection and Recurrence Prediction Across Solid Tumors
Real-world evidence shows high specificity and practical utility when tissue is unavailable, supporting relapse prediction, treatment surveillance and real-time resistance monitoring. Gene Solutions today announced the publication of a new
Highlight Takeaways from the APAC Precision Oncology Conference 2025
On November 1, Hong Kong hosted a regional meeting focused on the evolving role of precision oncology. The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in
A guide to Multi-Cancer Early Detection Testing (MCED) in Asia
MCED testing is emerging as an innovative solution in the fight against cancer, offering the ability to detect multiple types of cancer at earlier stages with just a single test.
CAP-Accredited Laboratory
Gene Solutions uniquely operates 2 CAP-accredited laboratories specializing in next-generation sequencing (NGS), within a network of 7 NGS laboratories in Asia.
Gene Solutions joins an esteemed group of laboratories worldwide. This rigorous process ensures that we not only meet but exceed the highest standards of care, ultimately delivering the best possible outcomes for our patients.
Gene Solutions Genomics Singapore Laboratory CAP#9709518
